To The Editor
Immunohistochemical analysis of ERa in breast cancer is now routine and plays a major role in the selection of appropriate adjuvant endocrine therapy in patients with this disease [1] . Nevertheless, the predictive value of such a test has been questioned due to problems associated with technical feasibility and reproducibility. A recent report in Breast Cancer Research and Treatment by Pentheroudakis et al. sought to address this issue by using the kinetic reverse-transcriptase polymerase chain reaction (kRT-PCR) technique to assess the predictive significance of ERa, PgR, and microtubule-associated protein Tau at the level of mRNA expression in early breast cancer [2] . This study was based on previous reports suggesting a satisfactory correlation of mRNA levels and protein levels as determined by IHC [3] [4] [5] . Despite this, after excluding chance agreement estimated by the Kappa co-efficient, their results revealed only a fair to moderate concordance between IHC and kRT-PCR determination of ERa (Kappa = 0.41) and PgR (Kappa = 0.33) expression [2] . Also, only a trend towards significance between ERa mRNA status and benefit from hormonal therapy in patients with early breast cancer was observed [2] .
ER exists as two genetically distinct isoforms, ERa and ERb, and it is now becoming clear that complex regulatory mechanisms exist for both subtypes. ERa mRNAs are produced from multiple different 5 0 UTRs that have differential effects on translation [6] . Furthermore, expression levels of ERa mRNAs containing specific 5 0 UTRs have been correlated with endocrine responsiveness in breast cancer patients [7] . Our own work on ERb demonstrates that two different ERb 5 0 UTRs have potent, yet differential, inhibitory effects on ERb translation and this contributes to deregulation of ERb expression in breast cancer [8] . In the case of progesterone receptor (PR), there is less direct evidence for a role for 5 0 UTRs in regulating protein expression. However, it is well established that the two functionally different human PR isoforms (A and B) are associated with different 5 0 UTRs [9], and variant forms of these UTRs appear to exist, at least within Genbank.
In conclusion, we suggest the complex regulatory mechanisms for members of the nuclear receptor superfamily, which are beginning to be unravelled, may provide an explanation for the inconsistencies observed between mRNA and protein expression. This casts doubt on the use of transcriptional profiling for predicting pathway activities or benefit from hormonal therapy in breast cancer. 
